Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study OPTIMISMM achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for the pomalidomide arm versus the comparator arm.

The J.P. Morgan Healthcare Conference is a yearly opportunity for the biopharma industry to make major announcements and allow analysts, investors and the media pick the brains of top execs. Here is a look at what four of the top big biopharma companies shared at the meeting.

Celgene Corp. forecast 2018 total revenue that fell short of analysts’ estimates, sending the company’s shares down 3 percent.

Amgen Inc. said the U.S. FDA approved its drug Xgeva to prevent fractures in patients with multiple myeloma.

Janssen Biotech Inc. entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen.

Sanofi management expressed confidence that the company’s pipeline of new products will support long-term growth.

Six months after losing its CEO, Galena Biopharma was absorbed in a reverse merger with Sellas Life Sciences to form a new company, Sellas Life Science Group Inc. The newly merged companies will focus on developing novel treatments for cancer.


AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.

Amgen announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and a variation to the marketing application to the European Medicines Agency to include overall survival data from the Phase 3 head-to-head ENDEAVOR trial in the product information for Kyprolis (carfilzomib).

Although a lot of attention went to unexpected data by China’s Nanjing Legend Biotech, bluebird bio and Celgene had CAR-T data of their own to brag about.